Management Options in Triple-Negative Breast Cancer | Zendy

Christina A. Minami | Zendy; D. Chung | Zendy; Helena R. Chang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management Options in Triple-Negative Breast Cancer

Author(s) -

Christina A. Minami,

D. Chung,

Helena R. Chang

Publication year - 2011

Publication title -

breast cancer basic and clinical research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.741

H-Index - 23

ISSN - 1178-2234

DOI - 10.4137/bcbcr.s6562

Subject(s) - triple negative breast cancer , medicine , breast cancer , disease , triple negative , cancer , oncology , clinical trial , targeted therapy , bioinformatics , biology

Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this review, we aim to give a broad overview of the disease's nomenclature and epidemiology, as well as the basic mechanisms of emerging targeted therapies and their performance in clinical trials to date.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research